Gregory Ochsner, MD
Radiation Oncology · Exton, PANPI 1689660011
Payments from drug & device makers
Across 165 payments — averaging $59.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Bayer$301
- Johnson & Johnson$278
- Novartis$227
- Merck$183
- Astellas Pharma US Inc$169
- plus $2K from 33 others
What the payments were for
- Consulting fees$5,80060%
- Food & beverage$3,89640%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 33 | $6,675 |
| Bayer | 13 | $301 |
| Johnson & Johnson(2 entities) | 16 | $278 |
| Novartis | 10 | $227 |
| Merck | 8 | $183 |
| Astellas Pharma US Inc | 8 | $169 |
| Siemens Medical Solutions USA, Inc. | 1 | $158 |
| Pfizer | 6 | $122 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Eisai Inc. | 5 | $114 |
| Genmab U.S., Inc. | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| AVEO Pharmaceuticals, Inc. | 3 | $95 |
| Incyte Corporation | 4 | $91 |
| Myriad Genetic Laboratories, Inc. | 6 | $90 |
| Daiichi Sankyo Inc. | 5 | $86 |
| Genentech USA, Inc. | 3 | $85 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| Myovant Sciences Inc. | 4 | $72 |
| Pharmacosmos Therapeutics Inc. | 3 | $63 |
| Sobi, Inc | 2 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $52 |
| GSK | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $41 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Mylan Institutional Inc. | 2 | $27 |
| Beigene USA, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| Accuray Incorporated | 1 | $22 |
| Telix Pharmaceuticals | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $21 |
| Sanofi | 1 | $21 |
| Amgen | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Aurobindo Pharma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$5,903
- Varian Ethos Treatment Planning$158
- OPDIVO$121
How this compares
$9,738 in reported general payments places this provider in the 80th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 79 | $1,065 |
| Oxycodone Hcl | 41 | $804 |
| Dexamethasone | 25 | $555 |
| Pantoprazole Sodium | 45 | $316 |
| Memantine Hcl | 13 | $251 |
| Lorazepam | 23 | $205 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $162 |
| Tramadol Hcl | 14 | $79 |
| Prednisone | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Exton
- David ClumpPittsburgh$3.2M
- Wenyin ShiPhiladelphia$1.1M
- Amit MaityPhiladelphia$1.1M
- Joseph CasterPhiladelphia$1M
- Abigail BermanPhiladelphia$924K
- Mitchell MachtayHershey$741K
- John PlastarasPhiladelphia$538K
- Justin BekelmanPhiladelphia$490K
- James MetzPhiladelphia$458K
- Andy MinnPhiladelphia$457K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.